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INTRODUCTION: 
Exomphalos is an anterior abdominal wall defect affecting 1 in 5000 neonates[1]. Up to 74% 
have other congenital anomalies including heart defects, chromosomal anomalies 
(especially Trisomy 13 and 18), Beckwith Wiedemann syndrome, and rarely midline 
syndromes (such as Pentalogy of Cantrell, OEIS (omphalocoele, exstrophy, imperforate 
anus and spinal) syndrome and lower midline syndrome)[2-4].  
If the abdominal wall defect is ≥5cm or contains liver, it is defined as exomphalos major; an 
important clinical distinction, as surgical management differs from exomphalos minor, which 
can usually be closed primarily. In exomphalos major there is significant abdomino-visceral 
disproportion which may make reduction of sac contents into the abdomen challenging or 
impossible. Traditionally management has been non-operative, leaving the sac to 
epithelialise to enable later surgical closure. Current surgical options include primary closure, 
(with or without a patch) and staged silo repair, which involves suturing a prosthetic silo to 
the defect edge, with or without sac excision. The silo is serially reduced over weeks, in 
theatre or at bedside. When the abdominal viscera are reduced, the silo is removed and 
abdominal wall closed.  Some authors advocate an aggressive surgical approach[5], but this 
institution has published a series managed with staged repair between 1997 and 2004[6] 
who had good outcomes. We sought to update this series and investigate whether 
congenital heart disease impacts on the surgical and other outcomes. Moreover, while some 
patient characteristics clearly influence outcome, such as respiratory failure at birth which is 
a significant predictor of mortality[7], it remains unclear whether infants with significant 
cardiac anomalies have worse outcomes. 
 METHODS: 
A retrospective review of infants with exomphalos major (defined as an abdominal wall 
defect of ≥5cm diameter with or without liver herniation) treated at Great Ormond Street 
Hospital was performed. Infants were included who presented from December 2004 to 
December 2014 inclusive (from the end of the previous study [6]). Infants were excluded if 
they had primary treatment elsewhere. The study was approved as an audit.   
Demographic data and details of comorbidities were obtained from notes and information 
about cardiac anomalies from echocardiogram reports. Cardiac anomalies were considered 
major if the patient required cardiac surgery or long term cardiology follow-up. The protocol 
for management was to offer primary closure if possible, and staged silo repair (as 
previously, leaving the sac intact[6]) if abdomino-visceral disproportion did not allow primary 
closure. Patients with severe comorbidities preventing  surgical intervention were managed 
conservatively and excluded from further analysis. Details of operative closure were 
obtained and outcomes compared between infants who had primary closure and staged 
repair with a silo and between those with and without significant cardiac anomalies.  
As exomphalos is associated with abnormal intestinal rotation, infants were investigated and 
offered Ladd’s procedure if necessary. Laparoscopic Ladd’s procedure is the institutional 
preference as it allows assessment of the rotational anomaly and the small bowel 
mesentery, with correction if necessary but reduced risk of adhesional bowel obstruction[8-
10]. 
Data are presented as median [range] and compared with two tailed Mann Whitney-U test, t 
test and Fishers exact test as appropriate using GraphPad Prism v5 (GraphPad Software, 
Inc., 2007).  
 RESULTS: 
Demographics and Patient Characteristics: 
Twenty two patients presented with exomphalos major. Liver was herniated in 20 and one 
had Pentalogy of Cantrell. Gestational age was 38 [30-40] weeks, birth weight 2.7 [1.4-4.6] 
kg; 13 (60%) were male. Eighteen patients (82%) were delivered by caesarean section, 12 
electively and 6 as an emergency.  
Cardiac anomalies were present in 20 (91%) infants, 8 had minor and 12 had major 
anomalies, some infants had more than one anomaly.  Minor anomalies included small PDA 
(patent ductus arteriosus, (PDA; 6), patent foramen ovale (PFO, 2) and small inter-atrial 
connection (2), none of which required surgical intervention or long-term follow-up. Major 
defects included PDA requiring intervention (7), ASD (atrial septal defect, 5), VSD 
(ventricular septal defect, 4), PFO requiring intervention (2), aortic arch abnormalities (3), 
DORV (double outlet right ventricle, 2), coarctation (1), tetralogy of Fallot (1), dilated left 
ventricle (1), right ventricular hypoplasia (1) and mitral valve anomaly (1). Twelve (55%) had 
other significant anomalies, including pulmonary hypoplasia with pulmonary hypertension (3) 
and congenital diaphragmatic hernia (2). 
Twelve (55%) had other anomalies, including pulmonary hypoplasia with pulmonary 
hypertension (3), congenital diaphragmatic hernia (1 Bochdalek, 1 Morgagni), undescended 
testes (3), renal abnormalities (1 duplex kidney, 1 pelvic kidney), talipes equinovarus (1) and 
hypothyroidism (1). Two infants had a chromosomal anomaly, x-linked ichthyosis (1) and 
Beckwith Wiedemann syndrome (1). Eight infants had inguinal herniae (5 bilateral and 3 
unilateral). 
Management: 
Two (9%) patients were managed conservatively due to overwhelming comorbidities, one 
had a left congenital diaphragmatic hernia and died on day two of life, the other had 
pulmonary hypoplasia and pulmonary hypertension, the sac was painted with betadine and 
saline and epithelialized. The patient died of respiratory distress syndrome precipitated by 
adenovirus infection 6 months later.  
All other infants (20/22; 81%) were managed surgically. Five (23%) infants underwent 
primary closure at 2 [1-7] days, the defect was 6cm [5-7cm] and all had liver herniation. In 4, 
full fascial closure was performed and in 1 only skin closure was possible. Four of these 
patients had major cardiac anomalies. [Figure 1] 
A staged approach was used in 15 (68%) infants – 7 with major cardiac anomalies and 8 
without, with silo application on day 1 [0-8]. Infants had a 6 [3-10] procedures to tuck the silo 
before definitive closure. 40% of tucks were at the bedside without anaesthetic (30/75). Age 
at definitive closure was 37 [9-112] days; 13 (87%) achieved full fascial closure, 2 were 
closed with a patch (Gore-tex® or permacol™). One patch became infected, requiring 
removal. One infant required silo refashioning 2 days after formation. Nine days later the sac 
ruptured; tissue expanders were used to increase the abdominal domain, but were replaced 
because of infection. Ultimately the abdominal wall was closed with a Strattice™ patch and 
plastic surgical reconstruction. One infant had an ileal perforation (presumed necrotizing 
enterocolitis) while the silo was in place and underwent laparotomy with oversewing of the 
perforation at day 28. Another two had exploration of bowel in the silo at day 5 and 9 due to 
suspected perforation. One infant had abdominal closure at day 20 but required silo 
refashioning at 30 days, the abdomen was subsequently closed at 70 days.  
The position of the duodeno-jejunal flexure was assessed in all infants, either at primary 
repair (5) or by contrast study after abdominal wall closure (15). Six infants (30%) had 
malrotation, none were symptomatic. Five had laparoscopic Ladd’s procedure at 5.5 [2.2-32] 
months, and one was assessed operatively, the mesentery was broad based, so Ladd’s 
procedure was unnecessary.  
Eleven (73%) patients in the staged closure group developed ventral herniae, compared to 1 
(20%) in the primary repair group (p=1).  
Primary outcomes:  
Infants who survived were followed up for 38 [2-71] months and no infants were lost to 
follow-up. Five (23%) patients died at 7 [0-17] months, including the two managed 
conservatively (described above), none primarily of the exomphalos. One infant in the 
primary closure group with coarctation of the aorta died at 27 days of sepsis and renal 
failure. Two who had delayed closure died from pulmonary hypertension with chronic lung 
disease (1 in the cardiac anomaly group, 1 not). Figure 1 shows outcome for all patients. 
Primary closure infants had fewer episodes of sepsis (1[0-1] vs. 2[1-4], p=0.009) but in 
staged infants there was no difference between those with and without cardiac anomalies 
(2[1-4] vs. 2[1-3], p=1). 
As expected, infants in the primary closure group had a shorter time to full closure (2 [1-7] 
vs. 37 [9-112] days, p<0.05) and a shorter hospital stay (13 [6-21] vs. 85 [19-159] days, 
p<0.05) but other outcomes were not different [Table 1, Figure 2]. 
Effect of cardiac anomalies: 
To examine the effect of major cardiac anomalies on outcome, we grouped the 20 surgically 
managed patients into those with major cardiac anomalies (n=11) and those with either a 
minor anomaly or no cardiac defect (n=9). There was no significant difference in gestation 
(38 [30-40] vs. 37 [35-38] weeks], p=0.1) or birth weight (2.7 [1.4-2.3] vs. 2.8 [2.3-4.6] kg, 
p=0.5) between infants with major cardiac anomalies and those without. Infants with cardiac 
anomalies had a shorter time to defect closure (13 [1-60] vs. 57 [1-112] days, p=0.01) but no 
significant difference in hospital stay (35 [6-139] vs. 84 [14-159] days, p=0.3), [Table 2, 
Figure 2]. 
Staged closure patients with cardiac anomalies were closed earlier than those without at 28 
[9-60] compared to 62 [17-112] days, p=0.03, [Table 2, Figure 2]. 
Patients with major cardiac anomalies had fewer procedures to achieve full closure (4 [1-9] 
vs. 9 [1-10], p=0.04) but if the primary closure group are excluded this apparent difference is 
not significant (5 [4-9] vs. 9 [3-10], p=0.09). 
There were no differences in ventilation duration, intensive care days, or time to full feeds 
between those with and without cardiac anomalies [Table 2], whether or not they had staged 
closure. There was also no difference in mortality between the two groups (2/11 with cardiac 
anomalies vs. 1/9 without, p=1). 
 
Discussion: 
Our results indicate that infants who underwent primary closure had a shorter time to closure 
and length of stay than those who had staged closure, as might be expected. However, 
there was no difference in duration of ventilation, intensive care stay or time to full enteral 
feeds. Obviously the decision of whether to opt for primary versus staged closure depends 
on factors including size of defect and stability of the patient, and is made at the time of the 
first surgery.We had hypothesised that infants with major cardiac anomalies would have 
worse outcomes than those without, but found this was not the case. Furthermore infants 
with major cardiac anomalies achieved abdominal wall closure earlier than those without. 
Major cardiac anomaly did not preclude primary closure, and was not associated with 
increased mortality. This is a retrospective review and the finding of shorter time to full 
closure may reflect a bias  and is unlikely to be of clinical significance. We think that the 
importance of these data is not that cardiac infants are closed more quickly, but that they do 
not require a longer time for closure. 
Management of exomphalos major continues to present a problem, with no consensus on 
optimal treatment and each method having challenges[11]. The paucity of good quality 
evidence is partly due to low incidence, with the majority of publications documenting case 
reports or small case series. Outcomes have improved in recent years regardless of 
technique, presumably as neonatal intensive care has improved.  
The definitive goal is to achieve both skin and fascial coverage of abdominal contents. 
Current approaches include surgery in the neonatal period or later. Initial non-operative 
management with sac epithelialisation and application of topical agents is favoured by 
many[12-16]. This may prevent respiratory complications and increased abdominal 
compartment pressure. However, it has disadvantages, including morbidity due to infection 
and wound complications, systemic absorption and toxicity of agents applied to the sac, and 
the requirement for later operative intervention[12-15,17].  
Many prefer neonatal repair[18]. Advocates of primary surgical closure highlight the benefits 
of reduced ventilation duration , shorter time to enteral feeds and reduced hospital stay when 
compared with staged closure [5]. However, the defect size, degree of viscero-abdominal 
disproportion and presence of associated anomalies, as in this study, may preclude 
reduction of abdominal viscera and immediate closure. 
A variety of methods of staged closure have been reported since Gross first described 
advancing skin flaps to cover the defect[19] . Staged silo reduction, as described in this, and 
other large series[5,6], is one such method, a modification of the technique described by 
Schuster[20]. Our practise is that patients with a silo remain in hospital. Closing with a silo 
allows earlier closure and aims for a fascial closure rather than a potentially more 
challenging procedure in childhood to close a large ventral hernia. Centres that opt for 
conservative management and later closure still usually keep the child in hospital until the 
sac has epithelialized which may also result in a prolonged hospital stay. 
This study is the first to assess if significant cardiac anomalies affect outcome in staged 
management of exomphalos major and is one of the largest series reviewing neonatal 
primary and staged closure. 
Our findings differ from those of a 2005 paper which demonstrated shorter duration of 
ventilation, intensive care stay and time to enteral feeds in primary closure compared with 
staged closure[5]. The observed differences in gestation and weight between the two groups 
in that study, unlike ours, may explain this difference. Interestingly, in our study, earlier 
gestation did not preclude primary closure. Ours is a centre for management of congenital 
cardiac anomalies, which may explain the higher incidence of significant cardiac anomalies 
(86%) than rates of 30-50% documented in the literature[5,21]. This may also have 
contributed to the similar outcomes we observed in the primary and staged closure groups; 
with a lower threshold for staged closure rather than pursuing a more aggressive strategy of 
primary closure. 
Infants with concomitant congenital anomalies, including cardiac, provide additional 
challenges when considering management of exomphalos major. Complications of staged 
reduction, such as respiratory insufficiency, haemodynamic compromise, prosthesis infection 
and inability to close the abdomen, lead many to adopt a more conservative approach. 
Furthermore, the severity of some anomalies may preclude neonatal operative intervention, 
as we found in two patients. Respiratory insufficiency at birth, in particular, has been shown 
to be an independent predictor of mortality in infants with giant exomphalos[7]. A study 
observed pulmonary hypertension in over a third of patients, associated with increased 
duration of ventilation and length of stay, but no difference between staged and delayed 
closure[22]. Another large series described infants managed with the Gross technique, either 
neonatally or after a conservative management, and found that major anomalies (including 
cardiac) had a greater effect on outcome than the surgical technique used, with a much 
higher mortality than found in our cohort (41% with major anomalies). This technique was 
however, associated with lower incidence of ventral hernia than our staged silo technique 
[23].  
Staged reduction has been reported in several series including a study demonstrating 
comparable survival outcomes to series documenting delayed closure[24]. However, due to 
the diverse nature of the anomalies, it is impossible to extrapolate any guidance as to which 
techniques should be applied to which populations. 
Interestingly this cohort of patients had more associated anomalies, including cardiac 
anomalies than the previous series reported from our centre, only 16% of whom had 
significant cardiac anomalies[6]. It is not clear whether this represents a change in referral 
patterns or obstetric practice, as studies of antenatally diagnosed exomphalos in recent 
years demonstrate a high termination rate [25,26]. One limitation of this study is that it was 
retrospective in nature and therefore some data, for instance accurate measurement of 
defect size, was inconsistently recorded. 
Our results demonstrate that patients with exomphalos major continue to present a 
challenge to paediatric surgeons and may have prolonged hospital stays if the defect cannot 
be closed primarily. Infants with significant cardiac anomalies can be managed with primary 
or staged closure, but do no worse than infants without major anomalies. These findings 
could be related to the early cardiologist involvement, but have the limitation related to any 
retrospective study. Prospective, studies such as the British Association of Paediatric 
Surgeons Congenital Anomalies Surveillance System (BAPS-CASS) national study, are 
necessary (https://www.npeu.ox.ac.uk/baps-cass/surveillance/exo). Nevertheless we believe 
this message is relevant for antenatal counselling, as parents can be informed that the 
cardiac anomaly does not affect the prognosis of the exomphalos, and does not need to 
dictate the surgical management.  
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Table 1 Primary Outcomes comparing Primary vs. Staged Closure 
 
Primary Closure Staged Closure 
 
N (%) 5 (23%) 15 (28%) 
 
Gestational age 
(weeks) 
37 [30-39] 38 [35-40] p=0.03 
Birth weight (kg) 2.8 [1.4-4.5] 2.7 [2.3-4.6] NS 
Mortality 1 (20%) 2 (13%) NS 
Number of procedures 
to close defect 
1 6 [3-10] p<0.0001 
Time to closure (days) 2 [1-7] 37 [9-112] p=0.007 
Time ventilated (days) 3 [1-25] 13 [1-48] NS 
Intensive care (days) 6 [4-25] 13 [3-139] NS 
Age at full feeds (days) 25 [6-44] 40 [13-141] NS 
Length of stay (days) 13 [6-21] 85 [19-159] p=0.02 
 
Table 2 Outcomes in Infants with Cardiac vs. No Cardiac anomalies 
 
Major cardiac 
anomaly 
No major cardiac 
anomaly 
 
N (%) 11(55%) 9(45%) 
 
Gestational age 
(weeks) 
38 [30-40] 37 [35-38] NS 
Birth weight (kg) 2.7 [1.4-4.3] 2.8 [2.3-4.6] NS 
Mortality 2 (18%) 1 (11%) NS 
Number of procedures 
to close defect 
4 [1-9] 9 [1-10] p=0.04 
Time to closure (days) 13 [1-60] 57 [1-112] p=0.01 
Time to closure (days) 
in staged patients 
28 [9-60] 62 [17-112] p=0.03 
Time ventilated (days) 9 [1-48] 11 [1-21] NS 
Intensive care (days) 9 [5-139] 19 [3-37] NS 
Age at full feeds (days) 32 [13-140] 53 [6-141] NS 
Length of stay (days) 35 [6-139] 84 [14-159] NS 
 
 
 Figure 2 Time to full closure of exomphalos 
 
 
